Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.43 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571677 | 0.83 | HPRT1 (0.44) | MAPTTRPV1HSD17B10MEN1KMT2A | |
| SCHEMBL931453 | 0.79 | MEN1 (0.53) | MAPTMEN1KMT2ALMNABLM | |
| SCHEMBL931472 | 0.79 | TRPV1 (0.52) | MAPTTRPV1HPGDKDM4EBLM | |
| SCHEMBL7376553 | 0.75 | HPRT1 (0.47) | MAPTTRPV1HSD17B10MEN1KMT2A | |
| SCHEMBL7375871 | 0.73 | HPRT1 (0.58) | MAPTHSD17B10MEN1KMT2AHPRT1 | |
| SCHEMBL930873 | 0.71 | HPRT1 (0.47) | MAPTHSD17B10MEN1KMT2AHPRT1 | |
| Water SCHEMBL6931313 | 0.71 | HPRT1 (0.46) | MAPTHSD17B10MEN1KMT2AHPRT1 | |
| SCHEMBL109158 | 0.70 | MAPT (0.73) | MAPTTRPV1HSD17B10MEN1KMT2A | |
| SCHEMBL7684221 | 0.70 | HPRT1 (0.45) | KMT2AHPRT1KDM4ENPC1CYP2C9 | |
| SCHEMBL7570897 | 0.70 | CA1 (0.50) | HSD17B10HPRT1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999057119-A1 | NOVEL DOPAMINE-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | claimed |
| WO-1999056550-A1 | METHOD FOR TREATING MIGRAINE IN MAMMALS | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | claimed |
| EP-1334103-B1 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | SPECTRUM PHARMACEUTICALS INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-6630490-B2 | Purine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6630478-B2 | Administering to patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002058736-A2 | USE OF 9-SUBSTITUTED PURINE ANALOGUES AND OTHER MOLECULES TO STIMULATE NEUROGENESIS | NEOTHERAPETICS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | EVE M. TAYLOR | 2002-07-11 | — | — | US | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6303617-B1 | FOR THERAPY OF OBESITY, LOWERING SERUM CHOLESTEROL AND HIGH DENSITY LIPOPROTEIN IN MAMMALS, INHIBITOR OF MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-16 | — | — | US | disclosed |
| WO-1999057120-A9 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS INC (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999057119-A1 | NOVEL DOPAMINE-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057119-A1 | NOVEL DOPAMINE-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057120-A1 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999056550-A1 | METHOD FOR TREATING MIGRAINE IN MAMMALS | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | MAPT 3440/4885TRPV1 767/4885HSD17B10 2184/4885 |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | DCX, MKI67, TK2 | MAPT 4186/4885TRPV1 370/4885HSD17B10 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.